PHARMACEUTICAL 2025

Royalty Pharma plc
Rank 66 of 225



PHARMACEUTICAL 2025

Royalty Pharma plc
Rank 66 of 225

The relative strengths and weaknesses of Royalty Pharma plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Royalty Pharma plc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 174% points.The greatest weakness of Royalty Pharma plc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 106% points.

The company's Economic Capital Ratio, given in the ranking table, is 290%, being 75% points above the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	1,802,139
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,253,616
Liabilities, Non-Current	6,626,733
Other Assets	16,420,576
Other Compr. Net Income	-471,830
Other Expenses	732,461
Other Liabilities	0
Other Net Income	38,369
Other Revenues	2,263,576
Property and Equipment	0
Research and Development	2,000
Selling, General and Administrative Expense	236,671

Output Variable	Value in 1000 USD
Assets	18,222,715
Liabilities	7,880,349
Expenses	971,132
Revenues	2,263,576
Stockholders Equity	10,342,366
Net Income	1,330,813
Comprehensive Net Income	1,094,898
BaseVar	14,923,986
ECR before LimitedLiability	181%
Economic Capital Ratio	290%